Colitis - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2017, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Colitis - Overview
Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Colitis - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Bristol-Myers Squibb Company
Concenter BioPharma Silkim Ltd
Cosmo Pharmaceuticals NV
CSA Biotechnologies LLC
Dr. Falk Pharma GmbH
EA Pharma Co Ltd
Genfit SA
Immuron Ltd
Innate Pharma SA
Ogeda SA
Peptinov SAS
Pfizer Inc
RDD Pharma Ltd
Saniona AB
Sigmoid Pharma Ltd
Soligenix Inc
Synovo GmbH
Colitis - Drug Profiles
AcTMP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-6899 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APY-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSA-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSY-0073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyloxalylglycine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESN-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06425090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPV-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-2007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPC-1022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL12 and IL23 for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL23 for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Colitis - Dormant Projects
Colitis - Discontinued Products
Colitis - Product Development Milestones
Featured News & Press Releases
Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Colitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Colitis - Pipeline by Akebia Therapeutics Inc, H1 2017
Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017
Colitis - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
Colitis - Pipeline by CSA Biotechnologies LLC, H1 2017
Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2017
Colitis - Pipeline by EA Pharma Co Ltd, H1 2017
Colitis - Pipeline by Genfit SA, H1 2017
Colitis - Pipeline by Immuron Ltd, H1 2017
Colitis - Pipeline by Innate Pharma SA, H1 2017
Colitis - Pipeline by Ogeda SA, H1 2017
Colitis - Pipeline by Peptinov SAS, H1 2017
Colitis - Pipeline by Pfizer Inc, H1 2017
Colitis - Pipeline by RDD Pharma Ltd, H1 2017
Colitis - Pipeline by Saniona AB, H1 2017
Colitis - Pipeline by Sigmoid Pharma Ltd, H1 2017
Colitis - Pipeline by Soligenix Inc, H1 2017
Colitis - Pipeline by Synovo GmbH, H1 2017
Colitis - Dormant Projects, H1 2017
Colitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Colitis - Discontinued Products, H1 2017